Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Immatics N.V.NASDAQ: IMTX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of €1.98M rose 669.6% year over year, ahead of the +138.9% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -18.5% a year.

Context

  • Accounts receivables amounted to 0.5% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Accounts receivables grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +669.6% holds above the trailing-twelve-month pace of +138.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.98M+168.6% QoQ
Last fiscal yearDec 2025
-€232.45K-86.8% YoY
LTMMar 2026
€1.5M+138.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+669.6%——
1 year-86.8%——
3-year CAGR-18.5%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

EUR · from the cash flow

Latest · FY2025
(232.45K) EUR
Year-over-year change
+86.8%

Accounts Receivables vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +138.9% is the 5th highest of 8, against a peer median of +210.6%.
  • Accounts receivables amounts to 4.0% of revenue for IMTX, versus a peer median of 9.2%.
IMTX Competitors
Accounts Receivables for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.89B EUR+210.6%-38.0%71.6%
LEGNLegend Biotech CorporationLTM Sep 2026$125.44M USD+174128.2%—9.2%
JANXJanux Therapeutics, Inc.LTM Mar 2026$35M USD+401.4%—161.9%
IMCRImmunocore Holdings plcLTM Mar 2026$16.59M USD+211.8%-40.8%4.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$8.88M USD-67.1%—38.4%
DTILPrecision BioSciences, Inc.LTM Mar 2026$5.47M USD-147.5%—12.1%
CLLSCellectis S.A.LTM Mar 2026$2.24M USD-96.4%-20.9%3.3%
IMTXImmatics N.V.LTM Mar 2026€1.5M EUR+138.9%-18.5%4.0%
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 USD——0.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD———
TCRXTScan Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding IMTX) —+210.6%-38.0%9.2%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.34M)37.51M(94.65M)15.22M(188.69M)
Depreciation & Amortization5.26M6.97M7.23M12.23M11.91M
Deferred Income Tax11.15M4.52M06.13M0
Stock-Based Compensation26.4M22.57M20.71M17.64M0
Change in Working Capital(31.7M)37.26M81.63M(163.88M)(42.23M)
Accounts Receivables569K(429K)(2.98M)(1.76M)(232.45K)
Inventory00(84.24M)00
Accounts Payables(31.78M)45.56M84.24M0(36.13M)
Other Working Capital(483K)(7.87M)84.61M(162.11M)(5.87M)
Other Non-Cash Items433K(8.7M)3.31M(45.37M)49.36M
Operating Cash Flow(81.78M)100.13M18.23M(158.03M)(169.66M)
Capital Expenditures(5.66M)(6.22M)(30.96M)(16.48M)(6.3M)
Acquisitions (Net)551K(199.91M)000
Purchases of Investments(11.3M)(216.32M)(415.33M)(450.35M)(324.92M)
Sales of Investments24.45M12.7M414.74M314.44M528.16M
Other Investing Activities(551K)199.96M(8K)(206K)0
Investing Cash Flow7.49M(209.79M)(31.39M)(152.39M)196.7M
Debt Repayment(2.71M)(2.84M)(3.85M)(2.01M)0
Common Stock Issued94K134.48M90.4M343.01M96.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(7.93M)(2.04M)(21.31M)(2.84M)
Financing Cash Flow(2.61M)123.71M84.52M319.68M93.51M
Effect of Forex Changes2.37M1.48M(1.4M)9.01M16.56M
Net Change in Cash(74.54M)15.53M69.95M18.28M137.12M
Free Cash Flow(87.44M)93.92M(12.73M)(174.51M)(175.95M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.